MedTrace Logo

A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

NCT00975767 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2015-01-08

No results posted yet for this study

Summary

The main purpose of this study is to assess the safety profile of MGCD265 when administered in combination with the marketed anticancer drugs erlotinib and docetaxel.

Conditions

  • Advanced Malignancies, Non-small Cell Lung Cancer

Interventions

DRUG

MGCD265+erlotinib

MGCD265 and erlotinib administered daily

DRUG

MGCD265+docetaxel

MGCD265 administered daily; docetaxel administered once every 3 weeks

Sponsors & Collaborators

  • Mirati Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Vanessa Tassell · MethylGene Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2013-07-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00975767 on ClinicalTrials.gov